Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study

Objective To determine whether joint synovitis and tendon friction rubs (TFRs) can predict the progression of systemic sclerosis (SSc) over time. Patients and methods We performed a prospective cohort study that included 1301 patients with SSc from the EUSTAR database with disease duration ≤3 years at inclusion and with a follow-up of at least 2 years. Presence or absence at clinical examination of synovitis and TFRs was extracted at baseline. Outcomes were skin, cardiovascular, renal and lung progression. Overall disease progression was defined according to the occurrence of at least one organ progression. Results Joint synovitis (HR: 1.26, 95% CI 1.01 to 1.59) and TFRs (HR: 1.32, 95% CI 1.03 to 1.70) were independently predictive of overall disease progression, as were also the diffuse cutaneous subset (HR: 1.30, 95% CI 1.05 to 1.61) and positive antitopoisomerase-I antibodies (HR: 1.25, 95% CI 1.02 to 1.53). Regarding skin progression, joint synovitis (HR: 1.67, 95% CI 1.06 to 2.64) and TFRs (HR: 1.69, 95% CI 1.02 to 2.77) were also independently predictive of worsening of the modified Rodnan skin score. For cardiovascular progression, joint synovitis was predictive of the occurrence of new digital ulcer(s) (HR: 1.45, 95% CI 1.08 to 1.96) and decreased left ventricular ejection fraction (HR: 2.20, 95% CI 1.06 to 4.57); TFRs were confirmed to be an independent predictor of scleroderma renal crisis (HR: 2.33, 95% CI 1.03 to 6.19). Conclusions Joint synovitis and TFRs are independent predictive factors for disease progression in patients with early SSc. These easily detected clinical markers may be useful for the risk stratification of patients with SSc.

[1]  R. Wise,et al.  The degree of skin involvement identifies distinct lung disease outcomes and survival in systemic sclerosis , 2013, Annals of the rheumatic diseases.

[2]  Oliver Distler,et al.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. , 2013, Arthritis and rheumatism.

[3]  R. Domsic,et al.  Significance of Palpable Tendon Friction Rubs in Early Diffuse Cutaneous Systemic Sclerosis , 2013, Arthritis care & research.

[4]  M. Matucci-Cerinic,et al.  Very early versus early disease: the evolving definition of the ‘many faces’ of systemic sclerosis , 2012, Annals of the rheumatic diseases.

[5]  Y. Allanore,et al.  Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings , 2012, Arthritis care & research.

[6]  Y. Allanore,et al.  Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies. , 2012, Rheumatology.

[7]  U. Müller-Ladner,et al.  Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database , 2012, Annals of the rheumatic diseases.

[8]  C. Boileau,et al.  Angiogenic biomarkers predict the occurrence of digital ulcers in systemic sclerosis , 2011, Annals of the rheumatic diseases.

[9]  R. Domsic,et al.  Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma , 2010, Annals of the rheumatic diseases.

[10]  J. Cracowski,et al.  Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies , 2010, The Journal of Rheumatology.

[11]  M. Matucci-Cerinic,et al.  Characteristics of Joint Involvement and Relationships with Systemic Inflammation in Systemic Sclerosis: Results from the EULAR Scleroderma Trial and Research Group (EUSTAR) Database , 2010, The Journal of Rheumatology.

[12]  D. Furst,et al.  Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. , 2010, Rheumatology.

[13]  D. Farge,et al.  Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis , 2009, Annals of the rheumatic diseases.

[14]  U. Müller-Ladner,et al.  The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy , 2009, Annals of the rheumatic diseases.

[15]  D. Furst,et al.  Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. , 2009, Arthritis and rheumatism.

[16]  E. Hachulla,et al.  Clinical Features of Scleroderma Patients With or Without Prior or Current Ischemic Digital Ulcers: Post-Hoc Analysis of a Nationwide Multicenter Cohort (ItinérAIR-Sclérodermie) , 2009, The Journal of Rheumatology.

[17]  M. Humbert,et al.  The 4th World Symposium on Pulmonary Hypertension. Introduction. , 2009, Journal of the American College of Cardiology.

[18]  U. Müller-Ladner,et al.  Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database , 2008, Annals of the rheumatic diseases.

[19]  M. Raza High N-Terminal Pro–Brain Natriuretic Peptide Levels and Low Diffusing Capacity for Carbon Monoxide as Independent Predictors of the Occurrence of Precapillary Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis , 2009 .

[20]  Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. , 2009, Journal of the American College of Cardiology.

[21]  E. Hachulla,et al.  Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. , 2007, The Journal of rheumatology.

[22]  Y. Allanore,et al.  New therapeutic strategies in the management of systemic sclerosis , 2007, Expert opinion on pharmacotherapy.

[23]  U. Müller-Ladner,et al.  Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database , 2007, Annals of the rheumatic diseases.

[24]  T. Medsger,et al.  Severe organ involvement in systemic sclerosis with diffuse scleroderma. , 2000, Arthritis and rheumatism.

[25]  T. Medsger,et al.  The palpable tendon friction rub , 1997 .

[26]  T. Medsger,et al.  The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. , 1997, Arthritis and rheumatism.

[27]  V. Steen,et al.  Autoantibodies in systemic sclerosis. , 1996, Bulletin on the rheumatic diseases.

[28]  A. Masi Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[29]  K. Harden,et al.  Pulmonary function tests. , 1959, Medical times.